NanoVibronix Inc (NAOV) - Total Assets
Based on the latest financial reports, NanoVibronix Inc (NAOV) holds total assets worth $54.38 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NAOV total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
NanoVibronix Inc - Total Assets Trend (2011–2024)
This chart illustrates how NanoVibronix Inc's total assets have evolved over time, based on quarterly financial data. Explore NanoVibronix Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
NanoVibronix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NanoVibronix Inc's total assets of $54.38 Million consist of 91.8% current assets and 8.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.7% |
| Accounts Receivable | $268.00K | 7.4% |
| Inventory | $2.19 Million | 60.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how NanoVibronix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NanoVibronix Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NanoVibronix Inc's current assets represent 91.8% of total assets in 2024, an increase from 86.9% in 2011.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, down from 82.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 60.4% of total assets.
NanoVibronix Inc Competitors by Total Assets
Key competitors of NanoVibronix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
NanoVibronix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 1.74 | 2.75 |
| Quick Ratio | 0.67 | 0.84 | 2.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.63 Million | $1.86 Million | $5.07K |
NanoVibronix Inc - Advanced Valuation Insights
This section examines the relationship between NanoVibronix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.04 |
| Latest Market Cap to Assets Ratio | 1.21 |
| Asset Growth Rate (YoY) | -45.6% |
| Total Assets | $3.63 Million |
| Market Capitalization | $4.37 Million USD |
Valuation Analysis
Above Book Valuation: The market values NanoVibronix Inc's assets above their book value (1.21x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: NanoVibronix Inc's assets decreased by 45.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NanoVibronix Inc (2011–2024)
The table below shows the annual total assets of NanoVibronix Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.63 Million | -45.62% |
| 2023-12-31 | $6.67 Million | +13.52% |
| 2022-12-31 | $5.88 Million | -31.81% |
| 2021-12-31 | $8.62 Million | +4.78% |
| 2020-12-31 | $8.23 Million | +304.17% |
| 2019-12-31 | $2.04 Million | +28.86% |
| 2018-12-31 | $1.58 Million | -67.52% |
| 2017-12-31 | $4.87 Million | +884.82% |
| 2016-12-31 | $494.00K | -75.09% |
| 2015-12-31 | $1.98 Million | +174.27% |
| 2014-12-31 | $723.00K | +4.63% |
| 2013-12-31 | $691.00K | +97.99% |
| 2012-12-31 | $349.00K | -67.83% |
| 2011-12-31 | $1.08 Million | -- |
About NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more